Updated on 1 October 2014
Novo Nordisk said that the needles were specifically designed to simplify the insulin injection process and make drug delivery more comfortable
Singapore: Malaysia-based, DKSH Holdings has inked a pact with Novo Nordisk Pharma Malaysia, for marketing and distributing Novo Fine 31G and 32G insulin needles among Malaysian pharmacies.
Novo Nordisk said that the needles were specifically designed to simplify the insulin injection process and make drug delivery more comfortable.
In a statement, the company said that this underscored DKSH Holdings' position as a partner of choice for distributing and marketing healthcare products across Asia. DKSH said that they were willing to partner with consumer health companies seeking to grow their brands in Asia.
Dr Marc Franck,vice president-Business Unit Healthcare, DKSH Malaysia, said, "The agreement reflected our strength, reputation, and unrivalled capillary distribution network in healthcare channels in Malaysia."
Mr Noha Shawky, general manager, Novo Nordisk Malaysia, said that the agreement will help in strengthening the company's healthcare brands in Malaysia and afford patients better access to diabetic care products.